Tuany Eichwald

Tuany Eichwald

Affiliated to Research
Visiting address: Solnavägen 9, Biomedicum, 17165 Solna
Postal address: C3 Fysiologi och farmakologi, C3 FyFa M Neuroimmunologi, 171 77 Stockholm

About me

  • Postdoctoral fellow in the Neuroimmunology group.

    Throughout my academic journey, I have gained extensive research experience that directly relates to my current interest in cancer neuroimmunology. My work focus on how sensory neurons modulate immune responses in the tumor microenvironment.

    Education:

    • Postdoctoral dellow (2023 - today) at Karolinska Institutet, Stockholm, Sweden.
    • Ph.D. Degree (2018-2023) at Universidade Federal de Santa Catarina, Brazil.
    • Master's Degree in Bioscience and Health (2016-2018) at Universidade do Oeste de Santa Catarina, Brazil.
    • Bachelor's Degree in Biomedicine (2010-2014) at Universidade do Oeste de Santa Catarina, Brazil.

Articles

All other publications

Grants

  • Brain Canada Foundation
    1 April 2024
    Melanoma brain metastases (MBMs) are a serious issue affecting up to half of all patients with stage IV melanoma, typically leading to a poor outlook. While immune therapy using anti-PD-1 can help, it only works for about 20% of MBM patients, which is much lower than the response seen in other melanoma patients who don’t have cancer affecting the brain. A combination of anti-PD-1 and anti-CTLA-4 therapies has shown some promise, with about half of patients responding well, though it does come with higher side effects. This combination treatment also loses its effectiveness for those with more severe MBMs. The unique environment in the brain for these tumors demands focused research. Recent studies have shown that the nervous system and immune system influence each other in complex ways. The peripheral nervous system impacts blood cell production, while the central nervous system manages inflammation and immune memory in other organs. Damage to nerves draws in macrophages, a type of immune cell, to help with healing. These cells play a role in cancer growth and in resistance to anti-PD-1 therapy. Studies have shown that these tumors can cause nerve damage which makes them resistant to common treatments. Patients whose tumors have spread into surrounding nerve tissues often do not respond well to therapy. Research has also shown that such nerve damage can trigger a series of immune responses that end up tiring out the cells meant to fight the tumor. Some experimental treatments in mice, like specifically turning off certain genes in nerves within the tumors, have shown that managing this nerve damage could potentially enhance the effectiveness of immune therapies. These discoveries are guiding new clinical trials that aim to improve treatment for brain tumor patients by specifically targeting the interactions between nerves and the immune system in tumors.

News from KI

Events from KI